IQVIA Holdings Inc. $IQV Shares Sold by Kestra Advisory Services LLC

Kestra Advisory Services LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 51.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,373 shares of the medical research company’s stock after selling 3,531 shares during the quarter. Kestra Advisory Services LLC’s holdings in IQVIA were worth $575,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new position in IQVIA during the 4th quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new stake in shares of IQVIA in the 1st quarter valued at approximately $25,000. International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at approximately $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. Finally, CrossGen Wealth LLC purchased a new position in IQVIA in the fourth quarter worth $28,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 0.1%

NYSE:IQV opened at $208.22 on Monday. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a fifty day simple moving average of $188.23 and a 200-day simple moving average of $187.05. The company has a market capitalization of $34.75 billion, a PE ratio of 25.80, a price-to-earnings-growth ratio of 1.87 and a beta of 1.20.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the prior year, the company earned $2.70 EPS. The firm’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

IQV has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research report on Thursday, July 9th. HSBC reiterated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Finally, Robert W. Baird lifted their price target on shares of IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $225.71.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.